Rofecoxib, diclofenac, and indomethacin increase risk of CVD

Comment

. 2006 Dec;55(12):1032.

No authors listed

Comment

No authors listed. J Fam Pract. 2006 Dec.

. 2006 Dec;55(12):1032.

No abstract available

Comment on

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P, Henry D. McGettigan P, et al. JAMA. 2006 Oct 4;296(13):1633-44. doi: 10.1001/jama.296.13.jrv60011. Epub 2006 Sep 12. JAMA. 2006. PMID: 16968831 Review.

Review: risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin but not celecoxib.
Bradley CP. Bradley CP. ACP J Club. 2007 Jan-Feb;146(1):24. ACP J Club. 2007. PMID: 17203943 No abstract available.
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Hudson M, Rahme E, Richard H, Pilote L. Hudson M, et al. Arthritis Rheum. 2007 Apr 15;57(3):516-23. doi: 10.1002/art.22614. Arthritis Rheum. 2007. PMID: 17394181
Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis.
Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, Chowienczyk P. Wong M, et al. Scand J Rheumatol. 2007 Jul-Aug;36(4):265-9. doi: 10.1080/03009740701286771. Scand J Rheumatol. 2007. PMID: 17763203 Clinical Trial.
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies.
de Koning L, Merchant AT, Pogue J, Anand SS. de Koning L, et al. Eur Heart J. 2007 Apr;28(7):850-6. doi: 10.1093/eurheartj/ehm026. Epub 2007 Apr 2. Eur Heart J. 2007. PMID: 17403720 Review.
A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
Mason RP, Walter MF, Day CA, Jacob RF. Mason RP, et al. Subcell Biochem. 2007;42:175-90. Subcell Biochem. 2007. PMID: 17612051 Review.